A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult Patients with Schizophrenia
A Study to Test if TV-46000 is Effective for Maintenance Treatment of Schizophrenia
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Enrolling: Male and Female Patients
IRB Number: 7685
U.S. Govt. ID: NCT03503318
Contact: Marlene Carlson, MPH: 646-774-8436 / mc157@columbia.edu
Additional Study Information: The purpose of this study is to evaluate the efficacy, safety and tolerability of different doses and durations of TV-46000 given by subcutaneous (under the skin) injection as compared to placebo for use as a potential maintenance in adults with schizophrenia.
This study is closed
Investigator
Joshua Kantrowitz, MD
Do You Qualify?
Do you have schizophrenia? Yes No
Are you between the ages of 18 - 55? Yes No
Are you / have you been on Clozapine? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Marlene Carlson, MPH
mc157@columbia.edu
646-774-8436
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE